Anyone can submit a Yellow Card report for non-trial use, including: Patients and members of the public GPs, pharmacists, nurses, and hospital clinicians Parents or carers reporting on behalf of another person For general queries about medicines safety or to find out more about the Yellow Card Scheme, patients can contact the MHRA directly or speak to their GP or pharmacist
Treatment is typically provided for up to 2 years within the NHS, and ongoing prescribing is contingent on demonstrating a clinically meaningful weight loss response usually assessed after reaching the maintenance dose or at around 6 months of treatment
Buvidal, available in Europe, UK, and Australia, offers both weekly and monthly formulations
Post-surgical swelling gradually resolves over the first three to six months, and scars continue to mature and fade for up to a year or longer
In internal medicine, patients rarely present with obesity in isolation
Comparing timing strategies with other GLP-1 medications If you have previously used semaglutide or tirzepatide, your timing experience with those medications provides useful but imperfect guidance for retatrutide